Fritz Offner
弗里茨·奥夫纳
MD, PhD
Professor of Hematology; Head, Department of Hematology血液学教授；血液科主任
👥Biography 个人简介
Fritz Offner, MD, PhD is Professor and Head of Hematology at Ghent University Hospital. A leading Belgian lymphoma investigator, he has contributed extensively to rituximab combination trials and lenalidomide-based immunomodulatory regimens in DLBCL, as well as HOVON cooperative group studies on aggressive lymphoma in elderly patients.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Rituximab Combinations and Immunomodulation in DLBCL
Led Belgian and international trials evaluating lenalidomide plus R-CHOP (R2-CHOP) and other rituximab combination strategies in newly diagnosed and relapsed DLBCL, with focus on non-GCB subtypes.
Elderly DLBCL Treatment Optimization
Contributed to HOVON studies defining reduced-intensity and attenuated regimens for elderly or unfit DLBCL patients, improving safety while preserving efficacy in this underserved population.
Representative Works 代表性著作
Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (REMARC trial)
Lancet Oncology (2017)
Phase III trial evaluating lenalidomide maintenance after R-CHOP in elderly DLBCL patients, demonstrating improved PFS in the lenalidomide arm.
Rituximab in combination with CHOP chemotherapy for diffuse large B cell lymphoma — updated Belgian experience
Leukemia & Lymphoma (2005)
Early Belgian cohort analysis confirming R-CHOP benefit across age groups and disease subtypes in routine clinical practice.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 弗里茨·奥夫纳 的研究动态
Follow Fritz Offner's research updates
留下邮箱，当我们发布与 Fritz Offner（Ghent University Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment